Your cart is empty.
Männedorf, Switzerland, April 18, 2012 – The Annual General Meeting of the Tecan Group (SIX Swiss Exchange: TECN) has today endorsed all motions proposed by the Board of Directors. The shareholders approved the Annual Report, the financial statements and the consolidated financial statements, and granted discharge to the Board of Directors and the Management Board. They also approved a significantly higher dividend versus the previous year of CHF 1.25 per registered share. The dividend will again be paid out from the available capital contribution reserve and is therefore not subject to withholding tax. The payout will take place on April 25, 2012.
The compensation report, which was submitted for an advisory vote for the first time, was accepted by shareholders. Tecan attaches great importance to good corporate governance. By putting the compensation report to an advisory vote, Tecan is fostering dialogue with shareholders on this key corporate management tool.
Rolf Classon, Heinrich Fischer, Dominique F. Baly, Gérard Vaillant, Dr. Oliver S. Fetzer and Erik Walldén were re-elected as Members of the Board of Directors of Tecan for a term of one year. Dr. Karen J. Huebscher was elected as new member of the Board of Directors. Rolf Classon, Chairman of the Board of Directors, thanked Dr. Lukas Braunschweiler, who is stepping down from the Board of Directors, for his valuable contribution and commitment.
Rolf Classon was confirmed as Chairman by the Board.
The shareholders also approved a change to the Articles of Incorporation which limits the Board of Directors' total authorization to define the capital structure. The approved capital was extended by two years, although in future only shares totaling around 20% of share capital may be issued under conditional and approved capital. This change will improve Tecan's corporate governance while preserving sufficient flexibility to take advantage of external growth opportunities.
KPMG AG, Zurich, was confirmed as statutory auditor for 2012.
Next date for the diary
The 2012 Interim Report will be published on August 16, 2012.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2011, Tecan generated sales of CHF 377 million (USD 424 million; EUR 306 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss security number: 1210019).
For further information
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89